Vertex Pharma sales tripled in second quarter

Hannah Blake

pharmaphorum

Vertex Pharmaceuticals has announced its second-quarter consolidated financial results – and revealed that its sales have increased by more than threefold to US $418.3 million from the year-earlier quarter.

"During the first half of the year, Vertex delivered several important advancements across our broad pipeline. In cystic fibrosis, we obtained U.S. and E.U. approval of KALYDECO earlier than anticipated, and we announced promising data for a combination of VX-809 and KALYDECO that accelerated our plans to begin a pivotal program early next year in people with the most common type of cystic fibrosis. We also announced today the first results for our nucleotide analogue ALS-2200, which enhance our portfolio of potential hepatitis C medicines and provide flexibility in the future development of multiple all-oral treatments for this disease."

Jeffrey Leiden, M.D., Ph.D., Chair, President and Chief Executive Officer of Vertex comments on the results.

Vertex believes it will remain at the forefront of treatments for hepatitis C and cystic fibrosis, as the company’s efforts to bring forward additional new medicines for other serious diseases continues to move forward rapidly.